
Highlighting the Impact of the TAP Network on International Clinical Trials Day
On International Clinical Trials Day, Cure Leukaemia celebrates the life-saving difference that clinical trials make to people living with blood cancer
Chronic Myeloid Leukaemia (CML) is a form of leukaemia where you have an increase in your white blood cells.
In CML, your bone marrow (the spongey part inside your bones) is producing too many myeloid cells, which are underdeveloped white blood cells that don’t work properly.
CML often develops slowly over several years, and is most common in people aged between 60 – 65.
Roughly, CML makes up 15 out of 100 leukaemia cases.
The majority of CML patients are asymptomatic, meaning little to no symptoms, and CML is only picked up through a blood test from their GP.
For some, where they have a much higher count of white blood cells, some patients experience:
– pain from an enlarged spleen
– Anemia
– Tiredness
– Bone pains
Treatment depends on if you’re asymptomatic or have a very high white blood cell count.
If you have a very high blood count, you could be put on a special machine that helps to skim off some of the extra white blood cells.
You could also be given medication to control and bring the white blood cell count down.
On International Clinical Trials Day, Cure Leukaemia celebrates the life-saving difference that clinical trials make to people living with blood cancer
Jonathan’s experience with the TAP-funded FEDORA Clinical Trial didn’t just improve his health—it gave him a second chance at life, highlighting the life-changing potential of clinical trials for patients with limited treatment options.
An emotional and inspiring evening unfolded at the Cure Leukaemia Leeds ATICUS event this week, as families, clinicians, and supporters came together to champion a bold new initiative to transform treatment for children with blood cancer.
Diagnosed with a rare and aggressive blood cancer affecting the brain, Caroline’s hope came through a groundbreaking clinical trial.